Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT02997982 Completed - Alzheimer Disease Clinical Trials

Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

VALZ-Pilot
Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of Valaciclovir treatment. Participants will be investigated using different measures before and after the treatment period.

NCT ID: NCT02997930 Completed - Clinical trials for Postoperative Delirium

fMRI Connectivity in Fracture Hip Patients

Start date: January 29, 2017
Phase: N/A
Study type: Interventional

The long-term goal of this study is to evaluate cognitive function preoperatively and develop techniques of intervention in the perioperative period which would optimize brain function and functional recovery following surgery.

NCT ID: NCT02992600 Completed - Clinical trials for Postoperative Cognitive Dysfunction

Postoperative Cognitive Dysfunction: Correlations With Olfactory Dysfunction and Related Gene Changes

Start date: December 2016
Phase:
Study type: Observational [Patient Registry]

To study on the Postoperative Cognitive Dysfunction: Correlations With Olfactory Dysfunction and Related Gene Changes.To explore whether the olfactory dysfunction could be used as a predictor of POCD and to provide reference for POCD prevention, early detection and timely diagnosis and treatment.

NCT ID: NCT02992327 Completed - Concussion, Mild Clinical Trials

Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)

BlacOut
Start date: August 30, 2015
Phase:
Study type: Observational

The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustaining a concussion. Concussion is also referred to as mild traumatic brain injury (mTBI) in the literature. Both terms will be used interchangeably throughout this application.

NCT ID: NCT02986958 Completed - Clinical trials for Cognitive Impairment

Involving Family to Improve Communication in Primary Care

SAMEPage
Start date: August 2016
Phase: N/A
Study type: Interventional

This study evaluates an agenda-setting checklist for patients with cognitive impairment and their family companions that is completed in the waiting room in advance of a primary care visit. The study team will conduct a two-group randomized trial to examine feasibility of the protocol and to compare medical communication (from visit audiotapes) during visits of patient-companion dyads who complete the checklist (n=50) with patient-companion dyads who receive usual care (n=50)

NCT ID: NCT02986659 Completed - Hypertension Clinical Trials

Genomic Outcomes of Metformin

GOMET
Start date: August 3, 2016
Phase: Phase 4
Study type: Interventional

Medical scientists have found that people with diabetes who take the drug Metformin have less age-related disease than those taking other treatments and researchers believe it may prevent numerous diseases and conditions that effect older people. In addition, metformin extends lifespan in some animal models of human disease. The purpose of this study is to see if taking Metformin causes changes in blood cells consistent with improved health and longevity in people who do not have diabetes. In this study Metformin will be compared to placebo. A placebo is a substance, like a sugar pill, that is not thought to have any effect on a participants disease or condition. In this study participants will either receive the active study medication, Metformin or placebo which is not active. Placebos are used in research studies to see if the drug being studied really does have an effect.

NCT ID: NCT02984540 Completed - Clinical trials for Mild Cognitive Impairment

Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease

BEAM
Start date: February 2015
Phase: N/A
Study type: Interventional

The purpose of the BEAM study is to compare the effects of a low-carbohydrate diet and a lowfat diet for adults with mild memory loss and adults with pre-diabetes. The data collected will help determine changes in cognitive function, brain structure and function, and levels of certain proteins and hormones in body fluids.

NCT ID: NCT02982603 Completed - Clinical trials for Mild Cognitive Impairment

Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment

Start date: May 2015
Phase: Phase 4
Study type: Interventional

This study is a 52-weeks, multicenter, randomized, double-blind, double- placebo, parallel controlled phase VI trial being carried out in 20 centers around China. The study population includes amnestic mild cognitive impairment patients (planned a total of 360) aged 55-85 in both gender. Participants will be randomly allocated to Qinggongshoutao bolus (7g per time,2 times per day) and placebo identified to Ginkgo biloba (Ginaton), Ginkgo biloba (Ginaton) (80mg per time, 2 times per day) and placebo identified to Qinggongshoutao bolus, or placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo biloba (Ginaton) for a 52-weeks double-blind treatment period. The primary outcome measure is change from baseline in the Alzheimer's Disease Assessment Scale- Cognition Subscale (ADAS-cog) and rate of conversion to dementia. The secondary outcomes are changes from baseline in the Mini-Mental State Examination(MMSE), Delayed Story Recall(DSR), Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24). Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.

NCT ID: NCT02982252 Completed - Clinical trials for Mild Cognitive Impairment

Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 2)

Start date: October 2016
Phase: N/A
Study type: Interventional

Losing the ability to walk can lead to fewer opportunities to socialize with friends and family and participate in the community. When this happens, powered wheelchairs can provide access to homes and communities, contributing to health and well-being. Training by a qualified occupational therapist allows an individual to use a powered wheelchair safely and effectively. Learning to drive a powered wheelchair can be difficult, frustrating and time consuming for people with cognitive and physical challenges. In this study, the investigators will ask participants with cognitive impairments to complete training with an occupational therapist using either a shared control wheelchair or training methods according to the standard of care. The investigators believe shared control training, entitled Collaborative Powered mobility Innovative Learning OpporTunity (CoPILOT) will enhance driving skill while maximizing safety learning. CoPILOT has the potential to enable people to participate more in their day to day lives and regain mobility independence.

NCT ID: NCT02979782 Completed - Delirium Clinical Trials

Neurological Outcome After Minimal Invasive Coronary Artery Bypass Graft

NOMICS
Start date: December 2016
Phase:
Study type: Observational

Primary objectives: Assessment of the incidence of postoperative cognitive dysfunction (POCD), cerebrovascular accident (CVA), and delirium after minimal invasive coronary artery bypass grafting (Endo-CABG). Secondary objectives: - Quality of life, three months after endo-CABG - Patient satisfaction with endo-CABG and the tests performed - The influence of various demographic and peri-operative variables on neurological outcome after endo-CABG - Incidence of fear and depression, 3 months after endo-CABG